Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04420793
Other study ID # 00089198
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 7, 2019
Est. completion date February 17, 2021

Study information

Verified date March 2021
Source Medical University of South Carolina
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Depressed patients talk differently when they are depressed compared to when they are well. But it is hard to actually measure what the differences are. The study team will record voice samples from patients with mood disturbances, like depression, over the course of their receiving an electroconvulsive therapy (ECT) series. The study team will try and measure or quantify exactly what has changed in their speech and voice. The study team will choose ECT as it is one of the most effective and rapid treatment for depression. The study team will use a service provided by a company, NeuroLex, who has complex computer programs (artificial intelligence, AI) to analyze the voice samples.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date February 17, 2021
Est. primary completion date February 17, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility INCLUSION CRITERIA: - Any candidate for electroconvulsive therapy who is about to initiate their ECT course at Medical University of South Carolina (MUSC) for a clinically indicated diagnosis - Age 18 to 90 years old - Able to speak and understand English - Able to give consent to participate in the study EXCLUSION CRITERIA: - Any medical condition that limits the ability to speak or speak clearly, for example a history of head and/or neck cancer, spinal cord injury affecting speech, amyotrophic lateral sclerosis, or those with absence of critical anatomical structures involved in speech. - Any voice characteristics that may limit the ability to speak English clearly including speech impediments or heavy accents (as evidenced by the pronunciation of the English language in such a non-standard way that research staff). If study staff have significant difficulty understanding the participant's responses in conversation, this may warrant exclusion. - Patients who are receiving ECT by involuntary order, by order of their guardian, or by a court order, as evidenced by patient report or brief chart review. - Patients who elect to not receive their full course of ECT at MUSC.

Study Design


Intervention

Other:
Questionnaire
3 voice recording tasks and 1 text entry task will be performed.

Locations

Country Name City State
United States Medical University of South Carolina Charleston South Carolina

Sponsors (1)

Lead Sponsor Collaborator
Medical University of South Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acoustic feature: zero crossing rate crossings per second Throughout a course of electroconvulsive therapy (ECT) which may last between 2 and 7 weeks.
Primary Acoustic feature: energy and entropy decibels Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Acoustic feature: spectral centroid, spectral spread, spectral entropy, spectral flux, spectral rolloff hertz Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Acoustic feature: Mel-Frequency Cepstral Coefficients, Chroma Vectors, and Chroma Deviation unitless Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic features: question ratio, filler ratio, number ratio, type token ratio unitless ratio Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic features: verb frequency, noun frequency, pronoun frequency, adverb frequency, adjective frequency, particle frequency, conjunction frequency, pronoun frequency percentage Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic features: standardized word entropy decibels/log(total word count) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic features: Brunets index W (lexical richness) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic features: Honores statistic R (lexical richness) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic features: rate of speech words per minute Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: fatigue Machine learning approach to evaluate binary outcome: fatigued or awake Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: audio quality Machine learning approach to evaluate binary outcome: bad or good Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: sentiment Machine learning approach to evaluate binary outcome: sad or happy Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: stress Machine learning approach to evaluate binary outcome: stressed or not stressed Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: gender Machine learning approach to evaluate binary outcome: male or female Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: accent Machine learning approach to evaluate a categorical outcome of accent region: england, indian, australian, etc. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: length seconds Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-features: age Machine learning approach to evaluate estimated decade-age: 10s, 20s, 30s, 40s, 50s, 60s, 70s, 80s, 90s, etc. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Comparing the voice feature(s) with greatest statistically significant change to Patient Health Questionnaire (PHQ)-9 scores The voice feature(s) found to have changed most significantly will be compared to Patient Health Questionnaire-9 scores which approach a total score that is less than 8, indicative of reduced depressive symptoms throughout Electroconvulsive Therapy Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Acoustic Feature Specific Changes within and across sessions Generalized mixed linear model will be used to evaluate which acoustic features change with P value threshold of <0.05 Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Linguistic Feature Specific Changes within and across sessions Generalized mixed linear model will be used to evaluate which linguistic features change with P value threshold of <0.05 Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Primary Meta-Feature Specific Changes within and across sessions Generalized mixed linear model will be used to evaluate which meta features change with P value threshold of <0.05 Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Acoustic Feature Specific Changes between sessions Acoustic voice features will be evaluated using continuous averages using one sample t-tests and we will be testing the difference over time to a null hypothesis of 0 (for no change) in the one sample t-test. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Linguistic Feature Specific Changes between sessions Linguistic voice features will be evaluated using continuous averages using one sample t-tests and we will be testing the difference over time to a null hypothesis of 0 (for no change) in the one sample t-test. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Meta-Feature Specific Changes between sessions Meta-voice features will be evaluated using continuous averages using one sample t-tests and we will be testing the difference over time to a null hypothesis of 0 (for no change) in the one sample t-test. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Age years Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: inpatient/outpatient status binary: inpatient or outpatient Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: gender male, female, unspecified Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: race african american, caucasian, hispanic, asian american, etc. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Psychiatric diagnosis for ECT Diagnosis indicated for receiving ECT Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: PHQ-9 score at each session Total (0-27) on 9 question scale Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Psychiatric hospitalizations Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Past Psychiatric Medication Trials Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Current Psychiatric Medication Trials Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Classes of Current Psychiatric Medications Categorical: Sedative, Selective Serotonin Reuptake Inhibitor, etc. Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Suicidal Ideation at ECT consult Binary: yes/no Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Past Suicide Attempts Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Psychiatric Review of Systems Descriptive, categorical Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Family Psychiatric History Categorical regarding psychiatric diagnoses of family members Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Number of non-psychiatric medical diagnoses Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Past non-psychiatric medication trials Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Current non-psychiatric Medications Number Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Tobacco use history Binary (yes/no) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Tobacco use pack year pack-year (total years smoked*average packs per day) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Prior ECT treatment Binary (yes/no) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: total # of prior ECT treatments for response in the past Numerical Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Prior transcranial magnetic stimulation (TMS) treatment Binary (yes/no) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data: Prior response to ECT or TMS Categorical Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Patient Chart Review Data against voice features We will evaluate voice features with statistically significant changes against respective participant chart review data using a general linear model with a clustering component for repeated measures which may also be applied to contrast statements evaluating overall change over time (from baseline to end). Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Generating ROC curves: stress Clinically determined stress level (mood) will be compared to meta-feature extractions of stressed vs. not stressed from voice recordings will be used to calculate an area under the receiver operating curve (AUOC) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Generating ROC curves: fatigue Clinically determined fatigue (motor) will be compared to meta-feature extractions of fatigued vs. awake from voice recordings will be used to calculate an area under the receiver operating curve (AUOC) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
Secondary Generating ROC curves: sentiment Clinically determined sentiment (affect and mood) will be compared to meta-feature extractions of happy vs. sad from voice recordings will be used to calculate an area under the receiver operating curve (AUOC) Throughout a course of electroconvulsive therapy which may last between 2 and 7 weeks.
See also
  Status Clinical Trial Phase
Completed NCT03256162 - Ketamine as an Adjunctive Therapy for Major Depression Phase 1
Recruiting NCT03396744 - Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression Phase 1/Phase 2
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Active, not recruiting NCT03641300 - Efficacy of Convulsive Therapies for Bipolar Depression N/A
Completed NCT02363738 - 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression Phase 2
Terminated NCT01807741 - Asenapine for Bipolar Depression Phase 2
Recruiting NCT01213121 - Neurophysiologic Changes in Patients With Bipolar Depression Phase 4
Completed NCT01919892 - Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium Phase 4
Completed NCT00762268 - A Trial of SAMe for Treatment-Resistant Bipolar Depression N/A
Terminated NCT00566111 - Ceftriaxone in the Management of Bipolar Depression N/A
Terminated NCT00217217 - Low Field Magnetic Stimulation Treatment for Bipolar Depression Phase 3
Recruiting NCT04998773 - Efficacy and Biomarkers of Response of TBS in Treatment Resistant Depression N/A
Recruiting NCT04939649 - Ketamine as an Adjunctive Therapy for Major Depression (2) Phase 3
Completed NCT03658824 - Behavioural Activation for Bipolar Depression: A Case Series N/A
Suspended NCT03674671 - Ketamine Versus Electroconvulsive Therapy in Depression Phase 3
Recruiting NCT05340686 - Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression N/A
Recruiting NCT05296356 - OSU6162 in Bipolar Depression (OBID) Phase 2
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Completed NCT02088580 - Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients N/A
Terminated NCT00272025 - Treatment Resistant Bipolar Depression Phase 1